GPCR

16.2105.32%
YM

Yingli Ma

Chief Technology Officer

Dr. Yingli Ma, Ph.D., has been the Chief Technology Officer at Structure Therapeutics Inc. (formerly known as ShouTi, Inc.). since August 2022 and served as its was General Manager & President of ShouTi Basecamp Bio from May 2021 until August 2022. Prior to joining ShouTi, Dr. Ma was site Head and General Manager of Amgen Biopharmaceutical R&D (Shanghai) from June 2020 to May 2021, responsible for Amgen's structural biology and China research platforms, supporting all preclinical drug discovery projects including small molecules and biologics in cardiometabolic, oncology and inflammatory disease areas. Previously, Dr. Ma served in various roles at Amgen, including Executive Director, Structural Biology and China Research Shanghai, or CNRS, Platforms from July 2018 to December 2019, and Principal Scientist, Structural Biology and Protein Expression from June 2014 to July 2018. Prior to serving at Amgen, Dr. Ma was Senior Scientist and Principal Scientist, Structural Chemistry Lead at GSK from April 2009 to May2014. Dr. Ma completed her post-doctoral fellowship in Molecular Biology at Rockefeller University. Dr. Ma obtained a Ph. D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and a B. S. in Clinical Medicine from China Medical University.

Positions